The basis of our therapeutic approach
The IOZK in Cologne specialises in translating current research findings in immunology into effective treatments for people suffering from cancer. Our group developed and enabled the translation of the first autologous tumour vaccine in Europe, which is approved along the regulatory guidelines in the Medicines Act for advanced therapies. This vaccine is based on an autologous dendritic cell platform loaded with autologous tumour antigens that recognise immunological danger signals and is aided by a virus.
Our tumour vaccine enables the patient’s immune system to actively eliminate the tumour. Current standard therapies try to fight the tumour, but do not take into account the potential of the body’s own defence mechanisms against tumour growth. Our therapy is based – adjacent to established therapies – on a combination of a specific immunotherapy that is tailored to the individual immunological and oncological needs of the patient. The term “personalised medicine” which is so often used today, is fully realised with our concept.
The complete cure of an advanced tumour can only be achieved in very rare cases through this type of therapy. But it can certainly influence the course of the disease positively and enhance the quality of life. Current results of our studies show an extended survival time when compared to the use of standard therapies alone.